Comparison of embryo results in in-vitro fertilization between progestin-primed ovarian stimulation and GNRH-Antagonist protocol at Tam Anh General Hospital
Main Article Content
Abstract
A retrospective study was conducted on 730 infertile women undergoing IVF, divided into two groups: PPOS with dydrogesterone (n = 365) and GnRH-ant (n = 365), to compare the effectiveness and safety of these protocols. There was no significant difference in baseline characteristics (age, BMI, AMH, AFC) between the two study groups. The number of good-quality day-3 embryos (4.85 ± 3.8 vs. 4.89 ± 3.52, p = 0.666), oocytes, mature (MII) oocytes, day-3 embryos, and blastocysts obtained were comparable between both groups. Total FSH dose also did not differ. However, the estradiol level on the hCG trigger day was significantly higher in the PPOS group . No moderate to severe OHSS cases were recorded in either group. The PPOS protocol using dydrogesterone yields similar outcomes as the GnRH-ant protocol in terms of oocyte and embryo quantity and quality. In conclusion, PPOS is a safe, convenient stimulation protocol and may be an effective alternative to GnRH-ant in IVF.
Article Details
Keywords
Progestin-primed ovarian stimulation, PPOS, dydrogesterone, GnRH antagonist, ovarian stimulation, in-vitro fertilization
References
2. The ESHRE Guideline Group on Ovarian Stimulation, Bosch E, Broer S, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI†. Human Reproduction Open. 2020; 2020(2):hoaa009. doi:10.1093/hropen/hoaa009.
3. Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016; 4(4): CD001750. doi:10.1002/14651858.CD001750.pub4.
4. Baum M, Machtinger R, Yerushalmi GM, et al. Recurrence of empty follicle syndrome with stimulated IVF cycles. Gynecol Endocrinol. 2012; 28(4):293-295. doi:10.3109/09513590.2011.631629.
5. Kuang Y, Chen Q, Fu Y, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015; 104(1): 62-70.e3. doi:10.1016/j.fertnstert.2015.03.022.
6. Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses | Human Reproduction Update | Oxford Academic. Accessed December 4, 2022. https://academic.oup.com/humupd/article/27/1/48/5917971?login=false.
7. Huang J, Xie Q, Lin J, et al. Progestin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: A Retrospective Cohort Study. Drug Des Devel Ther. 2019; 13:4461-4470. doi:10.2147/DDDT.S230129.
8. Nayar KD, Gupta S, Sanan S, et al. Progesterone primed ovarian stimulation protocol (ppos) vs gnrh antagonist for patients of freeze all cycles: a prospective randomised controlled trial. Fertility and Sterility. 2022; 118(4):e317. doi:10.1016/j.fertnstert.2022.09.088.
9. Which set of embryo variables is most predictive for live birth? A prospective study in 6252 single embryo transfers to construct an embryo score for the ranking and selection of embryos | Human Reproduction | Oxford Academic. Accessed August 21, 2024. https://academic.oup.com/humrep/article/30/1/28/684528?login=false.
10. Chen ZQ, Ai A, Zhang Y, et al. A randomized controlled trial to compare the live birth rate of the first frozen embryo transfer following the progestin-primed ovarian stimulation protocol vs. the antagonist protocol in women with an anticipated high ovarian response. Fertility and Sterility. 2024; 121(6):937-945. doi:10.1016/j.fertnstert.2024.01.027.
11. Yu S, Long H, Chang HYN, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018; 33(2):229-237. doi:10.1093/humrep/dex367.